1. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double‐blind, placebo‐controlled, phase III studies. Issue 7 (21st May 2013) Authors: Nitti, V. W.; Khullar, V.; van, P.; Herschorn, S.; Cambronero, J.; Angulo, J. C.; Blauwet, M. B.; Dorrepaal, C.; Siddiqui, E.; Martin, N. E. Journal: International journal of clinical practice Issue: Volume 67:Issue 7(2013) Page Start: 619 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. Issue 10 (22nd April 2014) Authors: Sievert, K.‐D.; Chapple, C.; Herschorn, S.; Joshi, M.; Zhou, J.; Nardo, C.; Nitti, V. W. Journal: International journal of clinical practice Issue: Volume 68:Issue 10(2014) Page Start: 1246 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and tolerability of the β3‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial. Issue 8 (6th April 2014) Authors: Nitti, V. W.; Chapple, C. R.; Walters, C.; Blauwet, M. B.; Herschorn, S.; Milsom, I.; Auerbach, S.; Radziszewski, P. Journal: International journal of clinical practice Issue: Volume 68:Issue 8(2014) Page Start: 972 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗